Last update 21 Nov 2024

Donepezil Hydrochloride

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDonepezil, a minuscule molecular compound, functions as an acetylcholinesterase inhibitor, indicating that it hinders the degradation of acetylcholine, a neurotransmitter in the brain, and provides assistance in enhancing cognitive function. Patients in mild, moderate, and severe stages of Alzheimer's Disease receive this drug as a therapeutic agent. Initially authorized in November 1996 by Eisai, a pharmaceutical establishment situated in Japan, it has now expanded to a worldwide availability. Although Donepezil Hydrochloride does not hold the cure for Alzheimer's Disease, it does assist in controlling some of the symptoms associated with the disease, such as memory loss, confusion, and other cognitive impairments. As a crucial medication for those existing with Alzheimer's Disease, it can amplify their quality of life and curtail the progression of the disease.

Drug Type

Small molecule drug

Synonyms

ARIPEZIL, BNAG, Domepezil

+ [44]

Target

AChE

Mechanism

AChE inhibitors(Acetylcholinesterase inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Lewy Body DiseaseAlzheimer DiseaseDementia+ [1]

Inactive Indication

Advanced cancerAttention Deficit DisorderCognitive Dysfunction+ [9]

Originator Organization

Eisai Co., Ltd.

Active Organization

Aulbio Co., Ltd.Startup

Eisai Co., Ltd.

Eisai, Inc.

+ [11]

Inactive Organization

Pfizer Inc.

Teikoku Pharma USA, Inc.

Corium, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (25 Nov 1996),

Alzheimer Disease

RegulationPriority Review (CN)

Structure

Molecular FormulaC24H30ClNO3

InChIKeyXWAIAVWHZJNZQQ-UHFFFAOYSA-N

CAS Registry120011-70-3

View All Structures (2)

358

Clinical Trials associated with Donepezil Hydrochloride

NCT06687993 / Not yet recruitingPhase 2IIT

Acetylcholinesterase Inhibitor Treatment in Anorexia Nervosa: a Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

The goal of this clinical trial is to learn if the daily take of donepezil can treat adult patient suffering from anorexia nervosa. The main question it aims to answer is : do daily donepezil intake permit weight gain and reduction of food restriction rituals ? The treatment is a capsule comprising a drug limiting the degradation of a neurotransmitter called acetylcholine. This treatment has long been used to treat certain cognitive disorders. Researchers will compare two drug dosage and a look-alike capsule that contains no drug to see if the dose has an impact on the effect. Participants will take one capsule per day for three months will have regular hospital visits for cognitive and metabolic tests.

Start Date01 Nov 2024

Sponsor / Collaborator

Centre Hospitalier Saint-Anne

[+2]

NCT05592678 / Not yet recruitingNot ApplicableIIT

Novel Methods for Clinical Trials in Dementia and Cognitive Decline

The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:
* Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status?
* Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity?
* Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?
* Is the effect of the intervention in fact medicated by changes in the targeted biomarker?
In this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called "adipokines"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.
Participants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

NCT06041789 / RecruitingPhase 2IIT

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease

People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism factors including bone mineral density, bone turnover markers, and bone quality.
Participants in this study will have a bone density test and have blood samples collected at the baseline study visit. Participants will then be randomly assigned to donepezil or matching placebo to be taken daily by mouth for 12 months. Blood samples will be collected at 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will also complete questionnaires at each study visit.

Start Date01 Oct 2024

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with Donepezil Hydrochloride

100 Translational Medicine associated with Donepezil Hydrochloride

100 Patents (Medical) associated with Donepezil Hydrochloride

4,793

Literatures (Medical) associated with Donepezil Hydrochloride

01 Feb 2025·Journal of Ethnopharmacology

Lancao decoction in the treatment of alzheimer's disease via activating PI3K/AKT signaling to promote ERK involving in enhancing neuronal activities in the hippocampus

Article

Author: Zhou, Hang ; Liu, Yuxin ; Zhang, Hailou ; Wu, Zhangjie ; Wu, Lei ; Shao, Mengqi ; Sun, Yan ; Yin, Ying ; Liu, Ruiyi ; Lu, Chao ; Zhu, Yaping

ETHNOPHARMACOLOGICAL RELEVANCEPrevious study has demonstrated lancao decoction (LC), a traditional Chinese medicine (TCM) fomula and recorded in "Huangdineijing", has a therapeutic effect on cognitive impairment (early clinical manifestations of alzheimer's disease (AD), which suggests that LC may have potential therapeutic advantages for AD. Whether LC has the therapeutic effect on AD and its potential mechanisms were still further indicated.AIM OF THE STUDYIn this study, we aimed to uncover the potential advantage and neuronal mechanisms of LC in the treatment of AD in APP/PS1 mice in the hippocampus.METHODS AND MATERIALSWe chose APP/PS1 mice to combing with behavioral tests including morris water maze (MWM) or y-maze to determine the role of LC in the therapeutic actions of AD. Network pharmacology was used to screen potential targets and pathways involving in LC's treatments of AD. Western blot was used to detect the phosphorylated expressions of proteins in hippocampus in APP/PS1 mice in the hippocampus. Pharmacological interventions were used to elucidate the relationship between the role of LC in the treatment of AD and the pathway, as well as the upstream and downstream interactions with neuronal activities.RESULTSAccording to our previous LC effective dose (2.5 g/kg), the dose was also able to significantly reduce the latency to the platform, and significantly increase the number of crossing times and time spend in the target quadrant in APP/PS1 mice in MWM, which was consistent with donepezil (DON) after 14 days chronic treatments. Network pharmacology showed that PI3K/AKT and MAPK pathways were closely associated with LC's treatments of AD, and protein autophosphorylation played a role in this process. The phosphorylated expressions of PI3K and AKT were obviously reduced in APP/PS1 mice in the hippocampus, which were both reversed by LC or DON. The phosphorylated expressions of MAPK including P38, JNK and ERK were also significantly reduced in APP/PS1 mice hippocampus, but only the phosphorylated expression of ERK was reversed by LC or DON. Inhibiting the activities of PI3K/AKT pathway by LY294002 blocked LC's improvement of behavioral deficits in APP/PS1 mice, including reducing latency to platform and increasing the number of crossings time in MWM in APP/PS1 mice, which also blunted LC's up-regulated phosphorylated expressions of PI3K, AKT and ERK in the hippocampus. Moreover, suppressing the activities of ERK by PD98059 also blocked LC's improvement of AD-related behavioral deficits including decreasing latency to new arm and increasing time in new arm in y-maze test, which also inhibited LC's enhancement of synaptic proteins (PSD95 and synapsin1) in the hippocampus and the number of EGR1-positive cells in the hippocampal dentate gyrus (DG).CONCLUSIONSTake together, our study revealed that LC had the therapeutic effects on AD by activating the PI3K/AKT pathway to enhance ERK activity and further strengthened neuronal activities in the hippocampus.

01 Feb 2025·Pharmaceutical Nanotechnology

Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Article

Author: Dalwadi, Saloni ; Prajapati, Bhupendra ; Thakkar, Vaishali

Background:Dementia associated with Alzheimer’s disease (AD) is a neurological disorder. AD is a progressive neurodegenerative condition that predominantly impacts the elderly population, although it can also manifest in younger people through the impairment of cognitive functions, such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic side effects.Objective:This work explores the use of data mining tools to optimize the formulation of NLCs comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective drugs and excipients are utilized for protecting the nervous system against damage or degeneration.Methods:The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication. NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM) of the high-speed homogenizer.Results:The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to 142.4±0.52 nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be - 26±0.36 mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged release of the formulation.Conclusion:The results indicate that NLCs have the potential to be a carrier for transporting medications to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically developing and optimizing NLC formulation.

01 Feb 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Streamlined turn-off fluorescence sensing of Donepezil: Enhancing evaluation in pharmaceutical formulations, quality control labs, and biological fluids at nano levels

Article

Author: Alsehli, Bandar R ; Abu-hassan, Ahmed A. ; El Hamd, Mohamed A. ; Abu-Hassan, Ahmed A ; Alsehli, Bandar R. ; Mahdi, Wael A ; Alshehri, Sultan ; El Hamd, Mohamed A ; Mahdi, Wael A. ; Abu-hassan, Ahmed A

Donepezil (DPZ) is used to treat Alzheimer's disease by increasing acetylcholine in the brain, necessitating precise analytical methods for its evaluation. This study aims to develop and validate a new turn-off fluorescence sensing method for quantifying DPZ, enhancing its evaluation in pharmaceutical formulations, quality control laboratories, and biological fluids. By leveraging the fluorescence-quenching interplay between DPZ and tetrabromofluorescein, the assay parameters were fine-tuned to enhance the development of an ion-associated complex. The developed method demonstrated a measurement range from 40.0 to 800.0 ng/mL, with detection and quantification limits of 12.6 ng/mL and 38.0 ng/mL, respectively. However, the successful application of the method to commercial DPZ tablets and plasma samples confirmed its effectiveness for both quality control labs and clinical research settings. It ensured accurate content uniformity and high precision, making it ideal for routine DPZ monitoring. In contrast to previous methods, this approach emphasizes environmental sustainability, evaluated using advanced tools like the Eco score scale, AGREE, RGB12, and BAGI. These tools facilitated a thorough assessment of the method's ecological impact and sustainability, underscoring its advantage over traditional methods in terms of environmental responsibility.

News (Medical) associated with Donepezil Hydrochloride

12 Nov 2024

·www.businesswire.com

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

VANCOUVER, British Columbia--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the pricing of its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts, commissions, and estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. All of the common shares are being offered by the Company. The offering is expected to close on November 13, 2024, subject to the satisfaction of customary closing conditions. The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is expected to begin trading on Nasdaq today, November 12, 2024. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYL TM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. “This offering serves as a tremendous milestone for Alpha Cognition, as we begin the commercialization of our FDA-approved drug, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer’s Disease,” said Michael McFadden, Chief Executive Officer and Director of the Company. "This financing puts our balance sheet in a position of meaningful strength and provides the necessary foundation for a successful commercial launch, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of ZUNVEYL and the exciting opportunity for our platform.” Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential closing of the Offering, the use of proceeds of the Offering, receipt of regulatory and stock exchange approvals in connection with Offering and completion of the Nasdaq uplisting. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

Drug ApprovalClinical Study

30 Jul 2024

·www.businesswire.com

New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer’s Disease Progression, and Response to Therapeutics

ORLANDO, Fla.--( BUSINESS WIRE )--Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their study, “ A functional aged human iPSC-cortical neuron model recapitulates Alzheimer’s disease, senescence, and the response to therapeutics ," has been published in the prestigious journal Alzheimer's & Dementia ® : The Journal of the Alzheimer's Association. doi.org/10.1002/alz.14044 AD affects an estimated 6.2 million Americans aged 65 and older, with projections suggesting this number could reach 14 million by 2050. Current treatments, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, provide only temporary relief. The high failure rate of AD clinical trials highlights the need for a better understanding of the pathophysiology and drug mechanisms. The study addresses a critical challenge in Alzheimer’s research: the degeneration of cortical layers associated with cognitive decline. Despite substantial efforts to date, few current AD therapies are not disease-modifying. The team accurately reproduced key biological aspects of aging and senescence in a multi-cellular microphysiological system (MPS), also known as a Human-on-a-Chip. This new approach reveals how cellular aging, also known as senescence, contributes to disease progression and therapy resistance, providing researchers with an accurate, human platform to further understand the disease and potential therapeutics in a living context. Further, since other platforms at Hesperos, based on neurodegenerative diseases, have been accepted by the Food and Drug Administration (FDA) for efficacy data, it provides a new method to accelerate development and regulatory submissions of new treatments. This model provides an invaluable tool for real-time measurement of neuronal activity and aging biomarkers, facilitating drug screening and the development of AD therapies. It also reveals complex disease mechanisms, such as the role of inflammatory factors in neuronal senescence and how it differs from non-disease age-related controls, offering new targets for intervention. Researchers cultured human iPSC-derived cortical neurons on patterned microelectrode arrays to measure long-term potentiation (LTP) noninvasively. LTP, a quantifiable metric for learning and memory, is directly impacted by central nervous system neurodegeneration. By treating these neurons with pathogenic amyloid-β (Aβ), a peptide that plays a central role in development of AD, to mimic disease pathophysiology, the team was able to analyze senescence and therapeutic responses. The study demonstrates that this novel human iPSC-cortical neuron model of aging, cultured in serum-free, defined conditions, accurately recapitulates hallmarks of AD showing the following: Pathological Insights : Aβ42 induced synaptic damage, accelerated neuronal senescence, impaired mitochondrial potential, and increased reactive oxygen species (ROS), leading to oxidative stress and inflammation. Therapeutic Responses : Drugs such as memantine, rolipram, saracatinib, and donepezil improved neuronal function and viability, though they did not completely halt Aβ42-driven senescence. The study underscores the potential of biomimetic MPS systems in translational research. By integrating clinically relevant neuronal function with proteome responses, this platform is poised to accelerate the discovery of novel neuroprotective compounds for AD and other neurological disorders. “This marks a significant step forward in Alzheimer's research by providing a deeper understanding of AD pathophysiology in a human aged MPS platform. We are excited about the potential of this model to transform drug discovery in AD, providing hope for patients,” said J. Hickman, PhD, co-founder and Chief Scientist of Hesperos and Professor of Chemistry at UCF. This research was supported by grants from the National Institutes of Health (R44TR001326, R44AG058330). Research Article : doi.org/10.1002/alz.14044 Nanoscience Technology Center (NSTC) at the University of Central Florida (UCF) The mission of the NSTC is to establish a cutting-edge research program in materials and nanotechnology, provide high quality training for students and facilitate the advance of innovations to solve real world technology challenges. https://nanoscience.ucf.edu/ Hesperos, Inc. Hesperos is a global contract research organization (CRO) providing drug development services using its Human-on-a-Chip ® platform - the most advanced, multi-organ microphysiological systems available today. https://hesperosinc.com

11 Jul 2024

·www.drugs.com

New Research Points Towards Potential Treatment for Anorexia

THURSDAY, July 11, 2024 -- Anorexia nervosa could be caused by lack of a specific brain chemical, reports a research team that has developed a possible cure for the eating disorder . Mouse studies have revealed that a deficit in acetycholine, a neurotransmitter associated with the brain’s reward system, could be linked to excessive habit formation. This deficit could be behind the compulsive self-starvation seen in people with anorexia, researchers argue in the July 7 issue of the journal Nature Communications . The Alzheimer's drug donepezil , which increases acetylcholine, “fully reversed the anorexia-like behaviour in mice, and we believe that it could potentially offer the first mechanism-based treatment of anorexia nervosa,” said senior researcher Dr. Salah El Mestikawy , professor of psychiatry with McGill University’s Douglas Research Center in Montreal. “In fact, we are already seeing its effects on some patients with the disease,” El Mestikawy added in a McGill news release. Positive results have already been seen in 10 patients with severe anorexia who are being treated with low doses of donepezil, researchers said. Three patients are in full remission from anorexia, and the other seven have shown marked improvements, results show. Full-fledged clinical trials comparing donepezil against placebo in treating anorexia are set to start later this year at three major hospitals in the United States and France, researchers said. However, El Mestikawy cautioned that it could take several years before a new drug targeting anorexia receives government approval and becomes available to patients. Donazepil causes many gastrointestinal and muscle side effects, El Mestikawy said. Researchers are working to develop a new drug that boosts acetylcholine with fewer problems. “We also suspect that other compulsive pathologies such as obsessive-compulsive disorders (OCD) and addictions can also be improved by donepezil, so we are actively looking for collaboration with other psychiatrist around the world to explore the possibilities,” El Mestikawy added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Donepezil Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00670	Donepezil Hydrochloride	N06DA02	DB00843

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lewy Body Disease	JP	Eisai Co., Ltd.	19 Sep 2014
Alzheimer Disease	US	Eisai, Inc.	25 Nov 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	KR	Icure Pharmaceutical Inc.	-
Attention Deficit Disorder	Phase 1	CL	Eisai Co., Ltd.	02 Jul 2008
Advanced cancer	Phase 1	US	Pfizer Inc.	01 Nov 2003
Sedation	Phase 1	US	Pfizer Inc.	01 Nov 2003
Dementia, Vascular	Phase 1	US	Eisai, Inc.	01 Mar 2003
Dementia, Vascular	Phase 1	US	Eisai, Inc.	01 Mar 2003
Parkinson Disease	Phase 1	GB	Eisai, Inc.	01 Mar 2003
Dementia	Phase 1	DE	Eisai Co., Ltd.	01 Aug 2002
Dementia	Phase 1	IE	Eisai Co., Ltd.	01 Aug 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04730635 (MK-0000-413, CTgov)	Phase 1	Alzheimer Disease \| Mild cognitive disorder	44	Donepezil (Donepezil)	ioozvzftxv(epblquvvxs) = cwlolythpt ibqnzuacuu (yoqfzmborg, xfrrevvujp - ljuhblypgr) View more	-	28 Oct 2024
				Placebo (Placebo)	ioozvzftxv(epblquvvxs) = nzohntoqtr ibqnzuacuu (yoqfzmborg, dmicyidoyw - dsfspvpfpl) View more
NCT04617782 (CTgov)	Phase 1	-	60	Donepezil (Treatment A 5 mg TDS)	mbckyrdwsy(wfuuthboas) = gttlqyvsla rfamikfkgx (hriuexrlkg, vqilhkjyki - ijrxgdummv) View more	-	19 Sep 2024
				Donepezil (Treatment B 10 mg TDS)	mbckyrdwsy(wfuuthboas) = vinxyredor rfamikfkgx (hriuexrlkg, suvgfsydrl - tzxurpuqvl) View more
NCT02822573 (Remember, CTgov)	Phase 3	Cognitive Dysfunction \| Breast Cancer	276	Donepezil 5 mg (Donepezil)	kytbwisvgl(onifgqcqdk) = pjrlqegrlt rfhondtktl (yizspgmfll, xpmniaunhz - gfqgwundev) View more	-	13 Sep 2023
				Placebo (Placebo)	kytbwisvgl(onifgqcqdk) = fbpxcgkajd rfhondtktl (yizspgmfll, uzjsikdyyj - tkvticovqb) View more
LIFE Study (AAIC2023)	Not Applicable	Alzheimer Disease First line	-	Newly prescribed donepezil	pwfgxqtyaq(xvbqqlxney) = ptfcwwhstf afpcqfrrxl (eeaoizmmof )	-	16 Jun 2023
AAIC2022	Not Applicable	Alzheimer Disease	-	Donepezil hydrochloride loaded chitosan nanoparticles	xarjgkuhdh(ljtowuugou) = wxjdrsqgom wvvcpnjpnx (azbxzwxusf ) View more	-	20 Dec 2022
NCT04617782 (Pubmed)	Phase 1	-	60	10-mg/d Corplex™ donepezil transdermal delivery system	kjxommdpoq(nfgmdpccca) = oral donepezil was associated with higher incidence of gastrointestinal AEs (14.5% versus 53.6%) vipmxxlniu (kheajeniym ) View more	-	16 Sep 2022
				5-mg/d Corplex™ donepezil transdermal delivery system
NCT04617782 (ANA2022)	Phase 1	-	-	Once-weekly 5-mg/d donepezil TDS	fwytcsigwf(mhetagppgp) = combined skin irritation score of ≥ 3 reported in 51.7% and 54.5% of participants, 0.5 hours after 5- and 10-mg/d TDSs removal, respectively xccacnprcw (hauxofsxmv )	-	14 Sep 2022
				Once-weekly 10-mg/d donepezil TDS
NCT00477659 (CTgov)	Phase 4	Alzheimer Disease	14	Donepezil hydrochloride	nadtogjwaa(delaehsalp) = mhufymsdnr kkkwgjvqxs (dxaultnyji, ljwuaxtsmt - uhiiufskoc) View more	-	10 Nov 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis